ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Croft SL, Coombs GH, 2003. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 :502–508.
-
2
Croft SL, Seifert K, Duchene M, 2003. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126 :165–172.
-
3
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
4
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33 :E57–E61.
-
5
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
6
Burroughs P, 2004. AEterna through its subsidiary Zentaris signs partnership with Roche in Brazil for new treatment of leishmaniasis, a devastating tropical diseases. Available at http://217.160.S7.239/en/content/downloads/20040202final.pdf.
-
7
Croft SL, Yardley V, Kendrick H, 2002. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 96 :S127–S129.
-
8
Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphophocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81 :151–157.
-
9
Evans DA, 1993. In vitro cultivation and biological cloning of Leishmania. Methods Mol Biol 21 :29–41.
-
10
Coderre JA, Beverley SM, Schimke RT, Santi DV, 1983. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci U S A 80 :2132–2136.
-
11
Dey T, Afrin F, Anam K, Ali N, 2002. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J Eukaryot Microbiol 49 :270–274.
-
12
Garcia AL, Kindt A, Llanos A, Bermudez H, Arevalo J, Banuls AL, Tibayrenc M, de Doncker S, Le Ray D, Dujardin J-C, 2005. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infection, Genetics and Evolution 8 :109–116.
-
13
Victoir K, De Doncker S, Cabrera L, Alvarez E, Arevalo J, Llanos-Cuentas A, Le Ray D, Dujardin JC, 2003. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 97 :80–87.
-
14
Tintaya KWQ, Ying X, Dedet JP, Rijal D, Bolle XD, Dujardin JC, 2004. Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase b and surface metalloprotease gp63 in the Leishmania donovani complex. J Infect Dis 189 :1035–1043.
-
15
Garcia L, Kindt A, Bermudez H, Llano-Cuentas A, Doncker SD, Arevalo J, Tintaya KWQ, Dujardin J-C, 2004. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 42 :2294–2297.
-
16
Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, Gamarro F, 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45 :2468–2474.
-
17
Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL, 2003. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22 :380–387.
-
18
Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J, Deloron P, 2003. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 47 :231–237.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 992 | 929 | 471 |
| Full Text Views | 300 | 14 | 1 |
| PDF Downloads | 95 | 11 | 2 |
THE SENSITIVITY OF CLINICAL ISOLATES OF LEISHMANIA FROM PERU AND NEPAL TO MILTEFOSINE
VANESSA YARDLEY
VANESSA YARDLEY
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by VANESSA YARDLEY in
Current site
Google Scholar
PubMed
Search for other papers by VANESSA YARDLEY in
Current site
Google Scholar
PubMed
SIMON L. CROFT
SIMON L. CROFT
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by SIMON L. CROFT in
Current site
Google Scholar
PubMed
Search for other papers by SIMON L. CROFT in
Current site
Google Scholar
PubMed
SIMONNE DE DONCKER
SIMONNE DE DONCKER
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by SIMONNE DE DONCKER in
Current site
Google Scholar
PubMed
Search for other papers by SIMONNE DE DONCKER in
Current site
Google Scholar
PubMed
JEAN-CLAUDE DUJARDIN
JEAN-CLAUDE DUJARDIN
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by JEAN-CLAUDE DUJARDIN in
Current site
Google Scholar
PubMed
Search for other papers by JEAN-CLAUDE DUJARDIN in
Current site
Google Scholar
PubMed
SIDDHARTHA KOIRALA
SIDDHARTHA KOIRALA
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by SIDDHARTHA KOIRALA in
Current site
Google Scholar
PubMed
Search for other papers by SIDDHARTHA KOIRALA in
Current site
Google Scholar
PubMed
SUMAN RIJAL
SUMAN RIJAL
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by SUMAN RIJAL in
Current site
Google Scholar
PubMed
Search for other papers by SUMAN RIJAL in
Current site
Google Scholar
PubMed
CESAR MIRANDA
CESAR MIRANDA
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by CESAR MIRANDA in
Current site
Google Scholar
PubMed
Search for other papers by CESAR MIRANDA in
Current site
Google Scholar
PubMed
ALEJANDRO LLANOS-CUENTAS
ALEJANDRO LLANOS-CUENTAS
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by ALEJANDRO LLANOS-CUENTAS in
Current site
Google Scholar
PubMed
Search for other papers by ALEJANDRO LLANOS-CUENTAS in
Current site
Google Scholar
PubMed
FRANCOIS CHAPPUIS
FRANCOIS CHAPPUIS
Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium; B P Koirala Institute of Health Sciences, Dharan, Nepal; Instituto Tropical “Alexander von Humbolt,” Lima, Peru; Hôpitaux Universitaires de Genève, Switzerland
Search for other papers by FRANCOIS CHAPPUIS in
Current site
Google Scholar
PubMed
Search for other papers by FRANCOIS CHAPPUIS in
Current site
Google Scholar
PubMed
Clinical isolates of Leishmania, from visceral leishmaniasis (VL) cases in Nepal and from cutaneous leishmaniasis (CL) cases in Peru, were cultured using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to type species and strain. Promastigotes from 38 isolates, within eight passages from isolation, were used to infect mouse peritoneal macrophage cultures in vitro, and the amastigote sensitivity to miltefosine was determined. The concentration required to kill 50% of intracellular amastigotes from Nepalese VL isolates, all typed as Leishmania (L.) donovani (N = 24) from both Sbv responders and nonresponders, ranged from 8.7 to 0.04 μg/mL. In contrast, the concentration required to kill 50% intracellular amastigotes from isolates from Peru, typed as L.(V.) braziliensis (N = 8), was > 30 to 8.4 μg/mL, L.(V.) guyanensis (N = 2) > 30 to 1.9 μg/mL, L.(L.) mexicana (N = 1) > 30 μg/mL, and L. (V.) lainsoni (N = 4) was 3.4 to 1.9 μg/mL. This demonstrates a notable difference in the intrinsic sensitivity of Leishmania species to miltefosine in vitro. If this model can be correlated to therapeutic outcome, it may have implications for the interpretation of clinical trials.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Croft SL, Coombs GH, 2003. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 :502–508.
-
2
Croft SL, Seifert K, Duchene M, 2003. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126 :165–172.
-
3
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347 :1739–1746.
-
4
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33 :E57–E61.
-
5
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38 :1266–1272.
-
6
Burroughs P, 2004. AEterna through its subsidiary Zentaris signs partnership with Roche in Brazil for new treatment of leishmaniasis, a devastating tropical diseases. Available at http://217.160.S7.239/en/content/downloads/20040202final.pdf.
-
7
Croft SL, Yardley V, Kendrick H, 2002. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg 96 :S127–S129.
-
8
Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphophocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81 :151–157.
-
9
Evans DA, 1993. In vitro cultivation and biological cloning of Leishmania. Methods Mol Biol 21 :29–41.
-
10
Coderre JA, Beverley SM, Schimke RT, Santi DV, 1983. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci U S A 80 :2132–2136.
-
11
Dey T, Afrin F, Anam K, Ali N, 2002. Infectivity and virulence of Leishmania donovani promastigotes: a role for media, source, and strain of parasite. J Eukaryot Microbiol 49 :270–274.
-
12
Garcia AL, Kindt A, Llanos A, Bermudez H, Arevalo J, Banuls AL, Tibayrenc M, de Doncker S, Le Ray D, Dujardin J-C, 2005. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infection, Genetics and Evolution 8 :109–116.
-
13
Victoir K, De Doncker S, Cabrera L, Alvarez E, Arevalo J, Llanos-Cuentas A, Le Ray D, Dujardin JC, 2003. Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis. Trans R Soc Trop Med Hyg 97 :80–87.
-
14
Tintaya KWQ, Ying X, Dedet JP, Rijal D, Bolle XD, Dujardin JC, 2004. Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase b and surface metalloprotease gp63 in the Leishmania donovani complex. J Infect Dis 189 :1035–1043.
-
15
Garcia L, Kindt A, Bermudez H, Llano-Cuentas A, Doncker SD, Arevalo J, Tintaya KWQ, Dujardin J-C, 2004. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J Clin Microbiol 42 :2294–2297.
-
16
Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, Gamarro F, 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45 :2468–2474.
-
17
Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL, 2003. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22 :380–387.
-
18
Aubouy A, Bakary M, Keundjian A, Mbomat B, Makita JR, Migot-Nabias F, Cot M, Le Bras J, Deloron P, 2003. Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother 47 :231–237.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 992 | 929 | 471 |
| Full Text Views | 300 | 14 | 1 |
| PDF Downloads | 95 | 11 | 2 |